Logo image of ALMDT.PA

MEDIAN TECHNOLOGIES (ALMDT.PA) Stock Fundamental Analysis

EPA:ALMDT - FR0011049824 - Common Stock

3.52 EUR
+0.01 (+0.28%)
Last: 9/10/2025, 7:00:00 PM
Fundamental Rating

2

Taking everything into account, ALMDT scores 2 out of 10 in our fundamental rating. ALMDT was compared to 11 industry peers in the Health Care Technology industry. Both the profitability and financial health of ALMDT have multiple concerns. ALMDT is quite expensive at the moment. It does show a decent growth rate.


Dividend Valuation Growth Profitability Health

Quickly go to:

1

1. Profitability

1.1 Basic Checks

ALMDT had negative earnings in the past year.
In the past year ALMDT has reported a negative cash flow from operations.
In the past 5 years ALMDT always reported negative net income.
In the past 5 years ALMDT always reported negative operating cash flow.
ALMDT.PA Yearly Net Income VS EBIT VS OCF VS FCFALMDT.PA Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 -5M -10M -15M -20M -25M

1.2 Ratios

The Return On Assets of ALMDT (-103.56%) is worse than 81.82% of its industry peers.
Industry RankSector Rank
ROA -103.56%
ROE N/A
ROIC N/A
ROA(3y)-75.23%
ROA(5y)-63.07%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ALMDT.PA Yearly ROA, ROE, ROICALMDT.PA Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 200 -200 -400 -600

1.3 Margins

The Gross Margin of ALMDT (103.86%) is better than 100.00% of its industry peers.
ALMDT's Gross Margin has been stable in the last couple of years.
ALMDT does not have Profit Margin and Operating Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM 103.86%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y1.46%
GM growth 5Y0.99%
ALMDT.PA Yearly Profit, Operating, Gross MarginsALMDT.PA Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 100 -100 -200

More info and screens

0

2. Health

2.1 Basic Checks

ALMDT does not have a ROIC to compare to the WACC, probably because it is not profitable.
Compared to 1 year ago, ALMDT has more shares outstanding
The number of shares outstanding for ALMDT has been increased compared to 5 years ago.
Compared to 1 year ago, ALMDT has a worse debt to assets ratio.
ALMDT.PA Yearly Shares OutstandingALMDT.PA Yearly Shares OutstandingYearly Shares Outstanding 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 5M 10M 15M
ALMDT.PA Yearly Total Debt VS Total AssetsALMDT.PA Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 10M 20M 30M 40M

2.2 Solvency

Based on the Altman-Z score of -9.66, we must say that ALMDT is in the distress zone and has some risk of bankruptcy.
ALMDT's Altman-Z score of -9.66 is on the low side compared to the rest of the industry. ALMDT is outperformed by 72.73% of its industry peers.
Industry RankSector Rank
Debt/Equity N/A
Debt/FCF N/A
Altman-Z -9.66
ROIC/WACCN/A
WACC7.19%
ALMDT.PA Yearly LT Debt VS Equity VS FCFALMDT.PA Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 20M -20M

2.3 Liquidity

A Current Ratio of 0.47 indicates that ALMDT may have some problems paying its short term obligations.
ALMDT's Current ratio of 0.47 is on the low side compared to the rest of the industry. ALMDT is outperformed by 81.82% of its industry peers.
A Quick Ratio of 0.46 indicates that ALMDT may have some problems paying its short term obligations.
Looking at the Quick ratio, with a value of 0.46, ALMDT is doing worse than 81.82% of the companies in the same industry.
Industry RankSector Rank
Current Ratio 0.47
Quick Ratio 0.46
ALMDT.PA Yearly Current Assets VS Current LiabilitesALMDT.PA Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 10M 20M 30M 40M

More info and screens

6

3. Growth

3.1 Past

The earnings per share for ALMDT have decreased by -8.88% in the last year.
ALMDT shows a small growth in Revenue. In the last year, the Revenue has grown by 3.25%.
ALMDT shows a strong growth in Revenue. Measured over the last years, the Revenue has been growing by 20.72% yearly.
EPS 1Y (TTM)-8.88%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-11.92%
Revenue 1Y (TTM)3.25%
Revenue growth 3Y3.75%
Revenue growth 5Y20.72%
Sales Q2Q%10.21%

3.2 Future

The Earnings Per Share is expected to grow by 26.15% on average over the next years. This is a very strong growth
Based on estimates for the next years, ALMDT will show a very strong growth in Revenue. The Revenue will grow by 22.17% on average per year.
EPS Next Y70.11%
EPS Next 2Y37.3%
EPS Next 3Y26.15%
EPS Next 5YN/A
Revenue Next Year10.15%
Revenue Next 2Y26.25%
Revenue Next 3Y22.17%
Revenue Next 5YN/A

3.3 Evolution

When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is stable.
ALMDT.PA Yearly Revenue VS EstimatesALMDT.PA Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2014 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 10M 20M 30M 40M
ALMDT.PA Yearly EPS VS EstimatesALMDT.PA Yearly EPS VS EstimatesYearly EPS VS Estimates 2020 2021 2022 2023 2024 2025 2026 2027 0 -0.5 -1

More info and screens

1

4. Valuation

4.1 Price/Earnings Ratio

ALMDT reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for ALMDT. No positive earnings are expected for the next year.
Industry RankSector Rank
PE N/A
Fwd PE N/A
ALMDT.PA Price Earnings VS Forward Price EarningsALMDT.PA Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 10 20

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
ALMDT.PA Per share dataALMDT.PA EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 0.5 -0.5 -1

4.3 Compensation for Growth

A more expensive valuation may be justified as ALMDT's earnings are expected to grow with 26.15% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y37.3%
EPS Next 3Y26.15%

More info and screens

0

5. Dividend

5.1 Amount

ALMDT does not give a dividend.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

MEDIAN TECHNOLOGIES

EPA:ALMDT (9/10/2025, 7:00:00 PM)

3.52

+0.01 (+0.28%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupHealth Care Equipment & Services
GICS IndustryHealth Care Technology
Earnings (Last)04-29 2025-04-29/amc
Earnings (Next)10-22 2025-10-22
Inst Owners18.08%
Inst Owner ChangeN/A
Ins OwnersN/A
Ins Owner ChangeN/A
Market Cap122.18M
Analysts85.45
Price Target8.87 (151.99%)
Short Float %N/A
Short RatioN/A
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DP0%
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)N/A
Avg EPS beat(2)N/A
Min EPS beat(2)N/A
Max EPS beat(2)N/A
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)-48.01%
PT rev (3m)-48.01%
EPS NQ rev (1m)N/A
EPS NQ rev (3m)N/A
EPS NY rev (1m)61.13%
EPS NY rev (3m)61.13%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)-6.55%
Revenue NY rev (3m)-9.76%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 5.32
P/FCF N/A
P/OCF N/A
P/B N/A
P/tB N/A
EV/EBITDA N/A
EPS(TTM)-1.37
EYN/A
EPS(NY)-0.4
Fwd EYN/A
FCF(TTM)-0.55
FCFYN/A
OCF(TTM)-0.52
OCFYN/A
SpS0.66
BVpS-0.98
TBVpS-1.04
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -103.56%
ROE N/A
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM 103.86%
FCFM N/A
ROA(3y)-75.23%
ROA(5y)-63.07%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y1.46%
GM growth 5Y0.99%
F-Score3
Asset Turnover0.94
Health
Industry RankSector Rank
Debt/Equity N/A
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 53.59%
Cap/Sales 4.71%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 0.47
Quick Ratio 0.46
Altman-Z -9.66
F-Score3
WACC7.19%
ROIC/WACCN/A
Cap/Depr(3y)102.16%
Cap/Depr(5y)84.24%
Cap/Sales(3y)5.46%
Cap/Sales(5y)4.28%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-8.88%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-11.92%
EPS Next Y70.11%
EPS Next 2Y37.3%
EPS Next 3Y26.15%
EPS Next 5YN/A
Revenue 1Y (TTM)3.25%
Revenue growth 3Y3.75%
Revenue growth 5Y20.72%
Sales Q2Q%10.21%
Revenue Next Year10.15%
Revenue Next 2Y26.25%
Revenue Next 3Y22.17%
Revenue Next 5YN/A
EBIT growth 1Y2.52%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year12.59%
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y11.62%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y11.31%
OCF growth 3YN/A
OCF growth 5YN/A